ExAblate therapy set for phase III US trials:
This article was originally published in Clinica
InSightec is to begin the final leg of US clinical trials for its non-invasive, MRI-guided, high frequency ultrasound ablation device. The phase III trials will assess the product, the ExAblate system, as a treatment for breast tumours, or fibroadenomas. The system is also being investigated for the treatment of uterine fibroids and breast cancer. InSightec was established at the beginning of 1999 as a joint venture between Elbit Medical Imaging and GE Medical Systems.